Daniel Aird
YOU?
Author Swipe
View article: TFEB and TFE3 have cell-type specific expression in the brain and divergent roles in neurons
TFEB and TFE3 have cell-type specific expression in the brain and divergent roles in neurons Open
Lysosomal dysfunction occurs in many neurodegenerative diseases, including Parkinson’s disease, and activating TFEB to enhance lysosomal biogenesis is a promising therapeutic strategy. To understand TFEB physiology in cells of the brain, w…
View article: Supplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S4 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal c…
View article: Supplementary Figure S5 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S5 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
LIG1 inactivation is lethal in HRD+ BRCA1/2 wild-type HCC1806 cells. A) Representative colony formation assay (treatment day 11) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in HCC1806 cells. B) …
View article: Supplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S2 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
CRISPRi system does not reduce viability of BRCA mutant cells using an intron-targeting control guide RNA (sgITC). Representative image (A) and quantification (B) of colony formation assay (treatment day 14) in MDA-MB-436 (BRCA1 mutant) ce…
View article: Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S6 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Perturbation of LIG1 induces proportional PAR accumulation in BRCA1-mutated cells in immunofluorescence and in-cell western assay formats. A) In-cell Western blotting of PAR on treatment day 4 in MDA-MB-436 cells engineered to express a DO…
View article: Data from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Data from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA lig…
View article: Supplementary Data from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Data from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Supplementary Materials
View article: Supplementary Figure S3 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S3 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Quantification of western blots for dTAG-mediated LIG1 degradation. MDA-MB-436 cells were engineered to express a CRISPR-resistant LIG1 cDNA fused to either the FKBP12mut (dTAG) degron (degradable) (A) or the FKBP12wt degron (non-degradabl…
View article: Supplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S7 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Withdrawal of Doxycycline leads to LIG1 depletion that is sustained through the study. Image (A) and quantification (B) of western blotting data from tumors of immunodeficient mice grafted with MDA-MB-436 cells engineered to express a DOX-…
View article: Supplementary Figure S1 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
Supplementary Figure S1 from LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Cell lines with damaging mutations in BRCA2 are dependent on LIG1. A) Analysis of DepMap data (28) comparing LIG1 dependence of cell lines with damaging mutations in BRCA2 vs. BRCA2 wild-type cell lines. ***p=0.0004 unpaired t-test. B,C) R…
View article: LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers
LIG1 Is a Synthetic Lethal Target in <i>BRCA1</i> Mutant Cancers Open
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA lig…
View article: Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma.
Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma. Open
Hepatocellular carcinoma (HCC) is an aggressive liver malignancy that is difficult to treat with no approved biomarker based targeted therapies. FGF19-FGFR4 signaling blockade has been recently identified as a promising avenue for treatmen…